Interferon Alpha

Phase 3Small molecule

AAinos, Inc. (f/k/a Amarillo Biosciences Inc.

Interferon Alpha is one of 323 small molecule programs targeting Polycythemia Vera. It is currently in Phase 3.

Indications

Total Trials

Active Trials

322

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

OsteosarcomaActive, not recruiting

LeukemiaActive, not recruiting

Social BehaviorActive, not recruiting

MelanomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

InfluenzaActive, not recruiting

Polycythemia VeraPhase 3

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

LeukemiaPreclinical

Active, not recruiting

Social BehaviorPreclinical

Active, not recruiting

MelanomaPreclinical

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Interferon Alpha

AAinos, Inc. (f/k/a Amarillo Biosciences Inc.

Phase 3

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Intron a

Abecma

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Lymphoproliferative Disorder

NCT00092222

Q2 2030

Phase 3Recruiting

Polycythemia Vera

NCT04116502

Clinical

Trials by Indication[1]

Osteosarcoma1 trial

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504140·30 enrolled

Influenza1 trial

Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment

Completed·AAinos, Inc. (f/k/a Amarillo Biosciences Inc.·Phase 2·NCT01146535·40 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Neuroendocrine Tumors1 trial

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

Completed·—·Phase 2·NCT02838342·28 enrolled

Treatment1 trial

Treatment of Oral Warts in HIV+ Patients

Completed·AAinos, Inc. (f/k/a Amarillo Biosciences Inc.·Phase 2·NCT00454181·59 enrolled

16 more indications

Multiple Myeloma1 trial

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

Completed·UUniversità Politecnica delle Marche·Phase 3·NCT00633542·103 enrolled

Hepatocellular Carcinoma1 trial

The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma

Withdrawn·FFudan University·N/A·NCT00838968

Melanoma1 trial

Cognitive Effects of Interferon in Patients With Melanoma

Completed·UUniversity of Arizona··NCT02074605·36 enrolled

Relapse1 trial

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Unknown status·PPeking University People's Hospital·Phase 4·NCT02027064·40 enrolled

T-cell Malignancies1 trial

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038376·56 enrolled

Leukemia1 trial

Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation

Withdrawn·PPeking University People's Hospital·N/A·NCT03121079

Social Behavior1 trial

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

Withdrawn·UUniversity of Arizona·N/A·NCT01625793

Renal Cancer1 trial

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

Completed·TThe Methodist Hospital Research Institute·Phase 2·NCT00445523·28 enrolled

Renal Cell Carcinoma1 trial

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Terminated·EEndocyte·Phase 2·NCT00485563·12 enrolled

Prevention1 trial

Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Completed·AAinos, Inc. (f/k/a Amarillo Biosciences Inc.·Phase 2·NCT00895947·200 enrolled

Polycythemia Vera1 trial

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Recruiting·UUniversity of Birmingham·Phase 3·NCT04116502·586 enrolled

Metastatic Cancer1 trial

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Completed·EEndocyte·Phase 1·NCT00329368·13 enrolled

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00062010·37 enrolled

Lymphoproliferative Disorder1 trial

Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00092222·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Interferon Alpha. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interferon Alpha compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interferon Alpha. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ainos, Inc. (f/k/a Amarillo Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAinos, Inc. (f/k/a Amarillo Biosciences Inc.

Interferon Alpha

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Trials by Indication[1]

Osteosarcoma1 trial

Influenza1 trial

Induction Chemotherapy1 trial

Neuroendocrine Tumors1 trial

Treatment1 trial

Multiple Myeloma1 trial

Hepatocellular Carcinoma1 trial

Melanoma1 trial

Relapse1 trial

T-cell Malignancies1 trial

Leukemia1 trial

Social Behavior1 trial

Renal Cancer1 trial

Renal Cell Carcinoma1 trial

Prevention1 trial

Polycythemia Vera1 trial

Metastatic Cancer1 trial

Type 1 Diabetes Mellitus1 trial

Gene Expression1 trial

Small Cell Lung Cancer1 trial

Lymphoproliferative Disorder1 trial

References

Drug Info

Quick Facts

Related News